A NOVEL VALIDATED STABILITY INDICATING ANALYTICAL METHOD FOR QUANTIFICATION OF EMPAGLIFLOZIN IN BULK AND MARKETED FORMULATION BY RP-HPLC APPLYING EXPERIMENTAL DESIGN APPROACH

Author:

Munde Manojkumar K., ,Kulkarni Nilesh S.,Rukhe Nikita B.,Sen Ashim K.,Sen Dhanya B.

Abstract

A stability indicating reversed-phase high-performance liquid-chromatographic method for analysis of empagliflozin was developed and validated as per the ICH guidelines. Statistical design of experiment was applied for optimization, where independent variables used were methanol proportions in mobile phase and flow rate. Experiment was carried out on an analytical reversed phase column Cosmosil C18 (250 × 4.6 mm, 5 µm). Based on the results obtained from these studies, suitable mobile phase with appropriate composition was selected and utilized for method development applying DoE approach. The mobile phase used was methanol: water (85:15 V/V). The flow rate was set at 0.8 mL min-1 and UV detection was carried out at 225 nm. The retention time of empagliflozin was found to be 4.259 min. The lower solvent consumption along with the short analytical run time (≤05 minute) provides a cost effective and environment friendly chromatographic procedure. The measured signal was shown to be precise, accurate and linear over the concentration range tested (10-50 µg mL-1) with a correlation coefficient of 0.9999. Thus, the proposed methodology is rapid, selective and requires simple sample preparation steps and represents a good procedure for analysis of empagliflozin. Central Composite Design (CCD) was used for method development of empagliflozin. Two factors were selected with eight center points and response of empagliflozin was measured in terms of retention time which dependent on two factors namely, methanol content in mobile phase and flow rate. CCD was effective means in optimization of HPLC for analysis of empagliflozin in pharmaceutical formulation. The stability of the drug was examined over different stress conditions as per International Conference on Harmonization (ICH) guidelines. Results obtained from the force degradation studies indicated that the developed method is appropriate for stability studies.

Publisher

Indian Drug Manufacturers' Association (IDMA)

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference14 articles.

1. 1. Inzucchi S. E., Zinman B., Fitchett D., Wanner C. and Schumacher M.: How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, 2018, 41(2) 356-363.

2. 2. Hinnen D.: Short commentary on empagliflozin and its potential clinical impact, Ther. Adv. Endocrinol. Metab., 2015, 6(2) 68-81.

3. 3. Padmaja N. and Veerabhadram G.: Method development and validation of RP-HPLC method for the estimation of empagliflozin in API, Int. J. Pharm. Sci. Res., 2016, 7(2) 724-727.

4. 4. Siridevi M. P., Kumar H. T., Rao S. Y. and Rao V. P. K.: RP-HPLC Method for Quantification of Empagliflozin in Pharmaceutical Formulation, Asian J. Pharm. Technol., 2019, 9(3) 208-211.

5. 5. Shirisha V., Krishnaveni B., Illendula S., Rao K. N. V. and Dutt H. R.: A new simple method development, validation and forced degradation studies of empagliflozin by using RP-HPLC, Int. J. Pharm. Biol. Sci., 2019, 9(1) 25-35.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3